1602 related articles for article (PubMed ID: 7604788)
41. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
Ceska R
Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
[TBL] [Abstract][Full Text] [Related]
42. Fluvastatin with and without niacin for hypercholesterolemia.
Jacobson TA; Chin MM; Fromell GJ; Jokubaitis LA; Amorosa LF
Am J Cardiol; 1994 Jul; 74(2):149-54. PubMed ID: 8023779
[TBL] [Abstract][Full Text] [Related]
43. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans.
Yuan JN; Tsai MY; Hegland J; Hunninghake DB
Atherosclerosis; 1991 Apr; 87(2-3):147-57. PubMed ID: 1854361
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.
Jacotot B; Banga JD; Pfister P; Mehra M
Br J Clin Pharmacol; 1994 Sep; 38(3):257-63. PubMed ID: 7826828
[TBL] [Abstract][Full Text] [Related]
45. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Tobert JA
Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
Leitersdorf E; Muratti EN; Eliav O; Meiner V; Eisenberg S; Dann EJ; Sehayek E; Peters TK; Stein Y
Am J Med; 1994 May; 96(5):401-7. PubMed ID: 8192170
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
Olsson AG; Pauciullo P; Soska V; Luley C; Pieters RE; Broda G; Palacios B;
Clin Ther; 2001 Jan; 23(1):45-61. PubMed ID: 11219479
[TBL] [Abstract][Full Text] [Related]
48. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
[TBL] [Abstract][Full Text] [Related]
49. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
[TBL] [Abstract][Full Text] [Related]
50. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
Davidson MH; Palmisano J; Wilson H; Liss C; Dicklin MR
Clin Ther; 2003 Nov; 25(11):2738-53. PubMed ID: 14693301
[TBL] [Abstract][Full Text] [Related]
51. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
[TBL] [Abstract][Full Text] [Related]
52. Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype.
Dergunov AD; Perova NV; Visvikis S; Siest G
Vascul Pharmacol; 2003 Dec; 40(5):237-45. PubMed ID: 15259790
[TBL] [Abstract][Full Text] [Related]
53. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
Eichstädt HW; Eskötter H; Hoffman I; Amthauer HW; Weidinger G
Am J Cardiol; 1995 Jul; 76(2):122A-125A. PubMed ID: 7604786
[TBL] [Abstract][Full Text] [Related]
54. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
55. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
[TBL] [Abstract][Full Text] [Related]
56. Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia.
Tatò F; Keller C; Wolfram G
Clin Investig; 1993 Apr; 71(4):314-8. PubMed ID: 8471818
[TBL] [Abstract][Full Text] [Related]
57. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
Samuelsson O; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Alaupovic P
Am J Kidney Dis; 2002 Jan; 39(1):67-75. PubMed ID: 11774104
[TBL] [Abstract][Full Text] [Related]
58. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome.
Toto RD; Grundy SM; Vega GL
Am J Nephrol; 2000; 20(1):12-7. PubMed ID: 10644862
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
[TBL] [Abstract][Full Text] [Related]
60. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
